文献速递外周动脉疾病

下肢血管造影评分系统与临床结局的系统综述

Clinical Outcomes Associated with Lower Limb Angiographic Scoring Systems: A Systematic Review.
PubMed 文献 · Ann Vasc Surg · 2026-01-14

该系统综述检索1977年至2025年2月的文献,纳入8项评估膝下动脉造影GLASS、TASC或Bollinger评分与临床结局关系的研究。GLASS在腔内治疗队列中可能与生存或保肢相关,但证据稀疏且质量差,在旁路队列中无一致关联。

要点

  • GLASS评分在腔内治疗患者中可能与总生存、无截肢生存或保肢相关,但证据不一致。
  • 在旁路手术队列中,GLASS分期与总生存、无截肢生存或保肢无一致关联。
  • TASC分类与临床结局无一致关联,Bollinger膝下评分仅单研究提示与总生存降低相关。

核心结论

  • 血管造影评分系统(GLASS、TASC、Bollinger)预测临床结局的证据稀疏且质量差。
  • GLASS评分可能与接受腔内治疗患者的临床结局相关,但对旁路手术的效用尚不明确。

研究设计与样本

  • 系统综述,检索Ovid MEDLINE、Embase和Cochrane Library从1977年至2025年2月28日。
  • 纳入所有关于成人膝下动脉造影使用GLASS、TASC或Bollinger评分并报告临床结局的出版物。
  • 共纳入8项研究:5项评估GLASS,2项评估TASC,1项评估Bollinger。

主要发现

  • 3项GLASS腔内治疗队列研究提示GLASS分期越高,总生存、无截肢生存或保肢越差;2项研究未发现关联。
  • 旁路手术队列中,GLASS分期与总生存、无截肢生存或保肢无相关性。
  • TASC分类与总生存、无截肢生存或保肢无一致关联。
  • 单项研究显示,较高的膝下Bollinger评分与总生存降低相关。

临床怎么用

  • 国际指南推荐在干预前使用GLASS、TASC等造影评分评估解剖严重程度,但现有证据不足以支持其常规用于预测生存或保肢。
  • GLASS评分或可辅助腔内治疗患者的风险分层,但需谨慎解读,尤其在旁路手术患者中。

局限性

  • 纳入研究数量少(8项),证据稀疏且质量差。
  • 终点和效应指标异质性大,仅能进行叙述性综合。
  • 未来研究需纳入踝下病变和侧支循环,并前瞻性验证预后性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic limb-threatening ischemia is associated with high rates of mortality and limb loss. International guidelines recommend assessing anatomic severity using angiographic scoring systems (Global Limb Anatomic Staging System [GLASS], Trans-Atlantic Inter-Society Consensus [TASC], Bollinger, etc.) before intervention; however, there is a paucity of evidence for their use, and few studies have examined their ability to predict clinical outcomes such as survival and limb salvage (LS). METHODS: We performed a systematic review searching Ovid MEDLINE, Embase, and Cochrane Library from 1977 to February 28, 2025. We included all publications on adult infrainguinal angiography evaluated using GLASS, TASC, or Bollinger reporting clinical outcomes. Given the heterogeneity of endpoints and effect measures, we conducted a narrative synthesis. RESULTS: Eight studies were included: 5 evaluated GLASS, 2 TASC, and one Bollinger. Three GLASS studies in endovascular cohorts suggested worse overall survival (OS), amputation-free survival (AFS), or LS with a higher GLASS stage, while 2 studies found no association. Across bypass cohorts, GLASS stage did not correlate with OS, AFS, or LS. TASC classification showed no consistent association with OS, AFS, or LS. A higher below-knee Bollinger score was associated with reduced OS in a single study. CONCLUSIONS: The evidence suggesting that angiographic scoring systems (GLASS, TASC, and Bollinger) predict clinical outcomes is sparse and of poor quality; the GLASS score may be related to clinical outcomes for those who undergo endovascular intervention, but its utility for bypass remains unclear. Future studies should incorporate inframalleolar disease and collateral circulation and prospectively validate the prognostic performance.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Lyons TJ, Kiruparan N, Ahmed M, et al. Clinical Outcomes Associated with Lower Limb Angiographic Scoring Systems: A Systematic Review. Ann Vasc Surg. 2026. PMID: 41544847. doi:10.1016/j.avsg.2025.12.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。